Latest & greatest articles for sepsis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on sepsis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on sepsis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for sepsis

281. Corticosteroids in the Treatment of Severe Sepsis and Septic Shock in Adults: A Systematic Review

Corticosteroids in the Treatment of Severe Sepsis and Septic Shock in Adults: A Systematic Review PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

2010 PedsCCM Evidence-Based Journal Club

282. Impact of continuous venovenous hemofiltration on organ failure during the early phase of severe sepsis: a randomized controlled trial

Impact of continuous venovenous hemofiltration on organ failure during the early phase of severe sepsis: a randomized controlled trial PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

2010 PedsCCM Evidence-Based Journal Club

283. Rapid molecular assays for the diagnosis of sepsis and identification of sepsis causing pathogens

Rapid molecular assays for the diagnosis of sepsis and identification of sepsis causing pathogens Rapid molecular assays for the diagnosis of sepsis and identification of sepsis causing pathogens Rapid molecular assays for the diagnosis of sepsis and identification of sepsis causing pathogens Mundy L, Hiller JE Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made (...) for the HTA database. Citation Mundy L, Hiller JE. Rapid molecular assays for the diagnosis of sepsis and identification of sepsis causing pathogens. Adelaide: Adelaide Health Technology Assessment (AHTA). Horizon Scanning Prioritising Summary Volume 27. 2010 Authors' conclusions The Prove-it™ assay provides rapid identification of a large number of bacterial species involved in sepsis infection once sepsis has been diagnosed by conventional means. Appropriate changes in patient antimicrobial therapy may

2010 Health Technology Assessment (HTA) Database.

284. The accuracy of the procalcitonin test for the diagnosis of neonatal sepsis: a meta-analysis

The accuracy of the procalcitonin test for the diagnosis of neonatal sepsis: a meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2010 DARE.

285. Updating the evidence for the role of corticosteroids in severe sepsis and septic shock: a Bayesian meta-analytic perspective

Updating the evidence for the role of corticosteroids in severe sepsis and septic shock: a Bayesian meta-analytic perspective Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2010 DARE.

286. Early identification of sepsis: a review of the evidence for clinical indicators and guidelines for management

Early identification of sepsis: a review of the evidence for clinical indicators and guidelines for management Early identification of sepsis: a review of the evidence for clinical indicators and guidelines for management Early identification of sepsis: a review of the evidence for clinical indicators and guidelines for management Canadian Agency for Drugs and Technologies in Health Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA (...) . No evaluation of the quality of this assessment has been made for the HTA database. Citation Canadian Agency for Drugs and Technologies in Health. Early identification of sepsis: a review of the evidence for clinical indicators and guidelines for management. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). 2010 Authors' conclusions Early diagnosis of sepsis: One systematic review of eight studies conducted in infants 0 to 2 months reported that signs of cyanosis, feeding difficulty

2010 Health Technology Assessment (HTA) Database.

287. Lactate clearance vs central venous oxygen saturation as goals of early sepsis therapy: a randomized clinical trial. Full Text available with Trip Pro

Lactate clearance vs central venous oxygen saturation as goals of early sepsis therapy: a randomized clinical trial. Goal-directed resuscitation for severe sepsis and septic shock has been reported to reduce mortality when applied in the emergency department.To test the hypothesis of noninferiority between lactate clearance and central venous oxygen saturation (ScvO2) as goals of early sepsis resuscitation.Multicenter randomized, noninferiority trial involving patients with severe sepsis

2010 JAMA Controlled trial quality: predicted high

288. Systematic review and meta-analysis of the efficacy of appropriate empiric antibiotic therapy for sepsis

Systematic review and meta-analysis of the efficacy of appropriate empiric antibiotic therapy for sepsis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2010 DARE.

289. B-type natriuretic peptide as a marker for sepsis-induced myocardial depression in intensive care patients

B-type natriuretic peptide as a marker for sepsis-induced myocardial depression in intensive care patients PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

2009 PedsCCM Evidence-Based Journal Club

290. Intrauterine inflammation, neonatal sepsis, and chronic lung disease: a 13-year hospital cohort study (Abstract)

Intrauterine inflammation, neonatal sepsis, and chronic lung disease: a 13-year hospital cohort study OBJECTIVE To determine the impact of intrauterine inflammation of maternal (chorioamnionitis) and fetal (umbilical vasculitis) origin and neonatal sepsis on the development of neonatal chronic lung disease in preterm infants.This study was conducted at Royal Prince Alfred Hospital in Sydney, Australia. All infants born at <30 weeks' gestation, admitted to the NICU, and surviving to 36 weeks (...) ' corrected gestation during 1992-2004 were eligible. Infants with major congenital abnormalities and those without placental examination were excluded. Antenatal and perinatal data extracted from hospital databases were correlated with the independent, central neonatal database and diagnostic laboratory reports. Neonatal sepsis was categorized according to blood culture isolates into 3 groups: coagulase-negative staphylococci, other bacteria, and Candida species.There were 798 eligible infants born

2009 EvidenceUpdates

291. A retrospective cohort study of prognostic factors associated with outcome in pediatric severe sepsis: what is the role of steroids?

A retrospective cohort study of prognostic factors associated with outcome in pediatric severe sepsis: what is the role of steroids? PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

2009 PedsCCM Evidence-Based Journal Club

292. Unfractioned heparin for treatment of sepsis: A randomized clinical trial (The HETRASE Study) (Abstract)

Unfractioned heparin for treatment of sepsis: A randomized clinical trial (The HETRASE Study) The primary aims of this study were to determine the effects of heparin on length of stay and change from baseline multiple organ dysfunction (MOD) score. Secondary objectives were to estimate the effects of heparin on 28-day all-cause mortality, and to determine the possible effect modification on 28-day all-cause mortality, in subgroups defined by site of infection and baseline values of Acute (...) not show any statistically significant reduction in 28-day mortality with UFH. There was only one serious adverse event on a patient who received heparin but it was fully resolved without complications.Our findings suggested that UFH may be a feasible and safe intervention in sepsis. However, this study was not able to demonstrate a beneficial effect on the chosen primary outcomes or in the 28-day mortality rate.

2009 EvidenceUpdates Controlled trial quality: predicted high

293. Oral lactoferrin for the treatment of sepsis and necrotizing enterocolitis in neonates. (Abstract)

Oral lactoferrin for the treatment of sepsis and necrotizing enterocolitis in neonates. Neonatal sepsis and necrotizing enterocolitis (NEC) cause significant neonatal mortality and morbidity in spite of appropriate antibiotic therapy. Enhancing host defence and modulating inflammation by using lactoferrin as an adjunct to antibiotics in the treatment of sepsis and/or NEC may improve clinical outcomes.The primary objective is to assess safety and efficacy of oral lactoferrin as an adjunct (...) to antibiotics in the treatment of neonates with suspected or confirmed sepsis and/or NEC.Relevant trials in any language were searched in June 2008 in the Cochrane Central Register of Controlled Trials (CENTRAL, The Cochrane Library), MEDLINE (1966 - June 2008), PREMEDLINE, EMBASE (1980 - June 2008), CINAHL (1982 - June 2008), web sites: www.clinicaltrials.gov and www.controlled-trials.com, abstracts from the annual meeting of Pediatric Academic Societies (1990- June 2008), by contacting authors who have

2009 Cochrane

294. Chlorhexidine maternal-vaginal and neonate body wipes in sepsis and vertical transmission of pathogenic bacteria in South Africa: a randomised, controlled trial. (Abstract)

Chlorhexidine maternal-vaginal and neonate body wipes in sepsis and vertical transmission of pathogenic bacteria in South Africa: a randomised, controlled trial. About 500,000 sepsis-related deaths per year arise in the first 3 days of life. On the basis of results from non-randomised studies, use of vaginal chlorhexidine wipes during labour has been proposed as an intervention for the prevention of early-onset neonatal sepsis in developing countries. We therefore assessed the efficacy (...) of chlorhexidine in early-onset neonatal sepsis and vertical transmission of group B streptococcus.In a trial in Soweto, South Africa, 8011 women (aged 12-51 years) were randomly assigned in a 1:1 ratio to chlorhexidine vaginal wipes or external genitalia water wipes during active labour, and their 8129 newborn babies were assigned to full-body (intervention group) or foot (control group) washes with chlorhexidine at birth, respectively. In a subset of mothers (n=5144), we gathered maternal lower vaginal swabs

2009 Lancet Controlled trial quality: predicted high

295. Bovine lactoferrin supplementation for prevention of late-onset sepsis in very low-birth-weight neonates: a randomized trial. Full Text available with Trip Pro

Bovine lactoferrin supplementation for prevention of late-onset sepsis in very low-birth-weight neonates: a randomized trial. Sepsis is a common and severe complication in premature neonates, particularly those with very low birth weight (VLBW) (<1500 g). Whether lactoferrin, a mammalian milk glycoprotein involved in innate immune host defenses, can reduce the incidence of sepsis is unknown. In animal models, the probiotic Lactobacillus rhamnosus GG (LGG) enhances the activity of lactoferrin (...) but has not been studied in human infants.To establish whether bovine lactoferrin (BLF), alone or in combination with LGG, reduces the incidence of late-onset sepsis in VLBW neonates.Prospective, multicenter, double-blind, placebo-controlled, randomized trial conducted in 11 Italian tertiary neonatal intensive care units. Patients were 472 VLBW infants enrolled from October 1, 2007, through July 31, 2008, and assessed until discharge for development of sepsis.Infants were randomly assigned to receive

2009 JAMA Controlled trial quality: predicted high

296. Diseases 2.0: Sepsis

Diseases 2.0: Sepsis Diseases 2.0: Sepsis – Clinical Correlations Search Diseases 2.0: Sepsis February 5, 2009 5 min read Diseases 2.0 – Bringing you the latest updates on disease pathophysiology and treatment Commentary by Andrew McKinstry MD PGY-1 Faculty Peer Reviewed For anyone who has stepped into an ICU, the septic patient is a familiar sight. Despite advances in research and management, including goal directed therapy and recombinant human activated protein C (Xigris), sepsis continues (...) to be a major cause of mortality in the critical care setting, with an estimated 215,000 deaths annually, and costing roughly 16.7 billion dollars per year. Despite these staggering human and monetary costs, the nature of and mechanisms involved in sepsis remain either unknown or hotly contested. The continuing research into this problem is on the verge of producing a number of promising insights and interventions, from insights into the nature of the syndrome to new pharmaceutical solutions and systems

2009 Clinical Correlations

297. The effects of steroids during sepsis depend on dose and severity of illness: an updated meta-analysis

The effects of steroids during sepsis depend on dose and severity of illness: an updated meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2009 DARE.

298. Statins for sepsis: a critical and updated review Full Text available with Trip Pro

Statins for sepsis: a critical and updated review Statins for sepsis: a critical and updated review Statins for sepsis: a critical and updated review Kopterides P, Falagas ME CRD summary This review investigated effectiveness of statins for treatment of sepsis. The authors concluded that statins had a beneficial effect on the outcome of infection, but could not make firm conclusions due to the poor quality of available data. This was an appropriate conclusion and is likely to be reliable (...) . Authors' objectives To assess the effectiveness of statins for treatment of sepsis. Searching PUBMED, EMBASE, Scopus and The Cochrane Library were searched up to 15 December 2008 without language restrictions (search terms were provided). Reference lists from identified articles, C and were searched. Study selection Studies that compared infection-related outcomes among patients who received and did not receive statins were eligible for inclusion provided they were full-text peer-reviewed articles

2009 DARE.

299. Granulocyte-macrophage colony stimulating factor administered as prophylaxis for reduction of sepsis in extremely preterm, small for gestational age neonates (the PROGRAMS trial): a single-blind, multicentre, randomised controlled trial. (Abstract)

Granulocyte-macrophage colony stimulating factor administered as prophylaxis for reduction of sepsis in extremely preterm, small for gestational age neonates (the PROGRAMS trial): a single-blind, multicentre, randomised controlled trial. Systemic sepsis is a major cause of death in preterm neonates. There are compelling theoretical reasons why treatment with haemopoietic colony-stimulating factors might reduce sepsis and improve outcomes, and as a consequence these agents have entered into use (...) in neonatal medicine without adequate evidence. We assessed whether granulocyte-macrophage colony stimulating factor (GM-CSF) administered as prophylaxis to preterm neonates at high risk of neutropenia would reduce sepsis, mortality, and morbidity.We undertook a single-blind, multicentre, randomised controlled trial in 26 centres between June, 2000, and June, 2006. 280 neonates of below or equal to 31 weeks' gestation and below the 10th centile for birthweight were randomised within 72 h of birth

2009 Lancet Controlled trial quality: predicted high

300. Procalcitonin-guided antibiotics in severe sepsis Full Text available with Trip Pro

Procalcitonin-guided antibiotics in severe sepsis Procalcitonin-guided antibiotics in severe sepsis | Critical Care | Full Text Advertisement Menu Search Search all BMC articles Search Menu We'd love your feedback. Please complete this 3 question Table of Contents , Eric B Milbrandt and Lillian L Emlet Critical Care 2008 12 :309 © BioMed Central Ltd 2008 Published: 4 December 2008 Citation Nobre V, Harbarth S, Graf JD, Rohner P, Pugin J: Use of procalcitonin to shorten antibiotic treatment (...) duration in septic patients: a randomized trial. Am J Respir Crit Care Med 2008, 177: 498–505 [ ]. Background The duration of antibiotic therapy in critically ill patients with sepsis can result in antibiotic overuse, increasing the risk of developing bacterial resistance. Procalcitonin (PCT)-guided antibiotic use reduces antibiotic exposure in community-acquired pneumonia. Whether it might also reduce antibiotic exposure in severe sepsis is unknown. Methods Objective To test the hypothesis

2009 Critical Care - EBM Journal Club